Fred Hassan

Fred Hassan
Name	Fred Hassan
Birth date	1945
Birth place	Pakistan
Nationality	American
Alma mater	University of London, Harvard Business School
Occupation	Business executive
Known for	CEO of Schering-Plough and Pharmacia

Fred Hassan. He is a prominent Pakistani-American business executive renowned for his transformative leadership in the global pharmaceutical industry. Hassan is best known for his tenure as CEO of Schering-Plough, where he engineered a major turnaround, and for his earlier role leading Pharmacia & Upjohn through a significant merger. His career is marked by strategic acquisitions, a focus on research and development, and influential board positions at major Fortune 500 corporations.

Early life and education

Born in Pakistan in 1945, Fred Hassan developed an early interest in science and business. He pursued his higher education in the United Kingdom, earning a degree in chemical engineering from the University of London. To further his business acumen, he later attended the prestigious Harvard Business School in the United States, where he completed the Advanced Management Program. This educational foundation in both technical and managerial disciplines prepared him for a career in the complex global healthcare sector.

Career at Schering-Plough

Fred Hassan initially joined Schering-Plough in the 1970s, holding various marketing and management positions that provided him with deep insight into the company's operations. During this early phase, he contributed to the promotion of key products like the antihistamine Claritin. His performance and strategic vision led to his appointment as head of the company's International division, where he gained valuable experience in global markets. This period was crucial for understanding the challenges and opportunities within the pharmaceutical industry.

Leadership at Pharmacia and Upjohn

In 1997, Hassan was recruited to become the CEO of Pharmacia & Upjohn, a company formed from the merger of Pharmacia of Sweden and the American firm Upjohn. Facing integration challenges and pipeline issues, he implemented a rigorous restructuring plan. His leadership was pivotal in strengthening the company's portfolio, which included the blockbuster arthritis drug Celebrex, developed in partnership with Pfizer. Hassan's successful stewardship made Pharmacia & Upjohn an attractive acquisition target for Pharmacia.

Tenure as CEO of Schering-Plough

Fred Hassan returned to Schering-Plough as its CEO in 2003, taking the helm during a crisis precipitated by the loss of patent protection for Claritin and manufacturing compliance issues cited by the U.S. Food and Drug Administration. He launched a comprehensive turnaround strategy dubbed the "Schering-Plough Value Creation Model." This involved cost-cutting, cultural transformation, and strategic deals, most notably the acquisition of Organon BioSciences from Akzo Nobel. His efforts stabilized the company and set the stage for its eventual $41 billion merger with Merck & Co. in 2009.

Post-CEO roles and board memberships

Following the Merck-Schering-Plough merger, Hassan transitioned to a career as a senior advisor and corporate director. He joined the private equity firm Warburg Pincus as a managing director and senior advisor, focusing on healthcare investments. His extensive board service includes directorships at Time Warner, Cisco Systems, and Avon Products. He also served as the non-executive chairman of the board for Bausch + Lomb and played a key role on the board of Sandoz, the generics division of Novartis.

Legacy and impact on the pharmaceutical industry

Fred Hassan is widely regarded as a master of corporate turnaround within the pharmaceutical industry. His legacy is defined by his patient-focused "Value Creation Model" and his ability to execute complex mergers and acquisitions, such as the Organon BioSciences deal and the Merck merger. He is frequently cited as an influential figure for his emphasis on ethical marketing and robust research and development. His career trajectory from Pakistan to the pinnacle of American business also makes him a notable figure in discussions of diversity in corporate governance.

Category:American businesspeople Category:Pakistani emigrants to the United States Category:Pharmaceutical industry executives